Sanpower to Buy U.S. Cancer-Drug Maker for $820 million

By Song Shiqing

(Beijing) — Sanpower Group Co. Ltd. has agreed to buy a U.S. maker of cancer vaccines for $820 million, marking the conglomerate’s largest move to date into the global industry for precision medicines.

The purchase is one of the largest-ever of an overseas drugmaker by a Chinese company. It will see Sanpower buy Dendreon, the U.S.-based cancer business of Canada’s Valeant Pharmaceuticals International Inc., Sanpower said in a statement on Tuesday.

You've accessed an article available only to subscribers
Try 4 weeks for $0.99
Share this article
Open WeChat and scan the QR code
Copyright © 2017 Caixin Global Limited. All Rights Reserved.